GlaxoSmithKline PLC Director/PDMR Shareholding (6484D)
20 Febbraio 2020 - 3:00PM
UK Regulatory
TIDMGSK
RNS Number : 6484D
GlaxoSmithKline PLC
20 February 2020
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Ms E Walmsley
=== ================================ ====================================================
b) Position/status Chief Executive Officer
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The exercise of nil-cost options over Ordinary
transaction Shares granted on 15 February 2017 under
the Company's 2009 Deferred Annual Bonus
Plan - Deferred Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 37,221 (Deferred)
=== ================================ ================ ==============================
GBP0.00 24,815 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 62,036
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ====================================================================================
a) Name Ms E Walmsley
=== ================================ ==================================================
b) Position/status Chief Executive Officer
=== ================================ ==================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ====================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ==================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ====================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ==================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of nil-cost
options under the Company's Deferred Annual
Bonus Plan - Deferred Bonus and Matching
Awards.
=== ================================ ==================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ =============== =============================
GBP16.614 17,523 (Deferred)
=== ================================ =============== =============================
GBP16.614 11,680 (Matching)
=============== =============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 29,203
Price GBP16.614
=== ================================ ==================================================
e) Date of the transaction 2020-02-17
=== ================================ ==================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ================================ ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Mr R Connor
=== ================================ ====================================================
b) Position/status President, Global Vaccines
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The exercise of nil-cost options over Ordinary
transaction Shares granted on 15 February 2017 under
the Company's 2009 Deferred Annual Bonus
Plan - Deferred Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 19,375 (Deferred)
=== ================================ ================ ==============================
GBP0.00 12,917 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 32,292
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===================================================================================
a) Name Mr R Connor
=== ================================ =================================================
b) Position/status President, Global Vaccines
=== ================================ =================================================
c) Initial notification/ Initial notification
amendment
=== ================================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== ================================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of nil-cost
options over Ordinary Shares under the
Company's Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
=== ================================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ===========================
GBP16.714 9,120 (Deferred)
=== ================================ ================ ===========================
GBP16.714 6,081 (Matching)
================ ===========================
d) Aggregated information
===
Aggregated volume 15,201
Price GBP16.714
=== ================================ =================================================
e) Date of the transaction 2020-02-17
=== ================================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ================================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Mr N Hirons
=== ================================ ====================================================
b) Position/status SVP, Global Ethics and Compliance
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The exercise of nil-cost options over Ordinary
transaction Shares granted on 15 February 2017 under
the Company's 2009 Deferred Annual Bonus
Plan - Deferred Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 12,243 (Deferred)
=== ================================ ================ ==============================
GBP0.00 8,163 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 20,406
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===================================================================================
a) Name Mr N Hirons
=== ================================ =================================================
b) Position/status SVP, Global Ethics and Compliance
=== ================================ =================================================
c) Initial notification/ Initial notification
amendment
=== ================================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== ================================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of nil-cost
options over Ordinary Shares under the
Company's Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
=== ================================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ===========================
GBP16.678 5,770 (Deferred)
=== ================================ ================ ===========================
GBP16.678 3,846 (Matching)
================ ===========================
d) Aggregated information
===
Aggregated volume 9,616
Price GBP16.678
=== ================================ =================================================
e) Date of the transaction 2020-02-17
=== ================================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ================================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =====================================================================================
a) Name Mr B McNamara
==== ================================== =================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =====================================================================================
a) Name GlaxoSmithKline plc
==== ================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =====================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ================================== =================================================
b) Nature of the The sale of ADSs to meet tax liabilities
transaction on the vesting of awards under the Company's
Deferred Annual Bonus Plan - Deferred Bonus
and Matching Awards.
==== ================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ================================== ================ =============================
$43.544 3,467 (Deferred)
==== ================================== ================ =============================
$43.544 2,423 (Matching)
================ =============================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price 5,890
$43.544
======================================= =================================================
e) Date of the transaction 2020-02-18
==== ================================== =================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Mr D Redfern
=== ================================ ====================================================
b) Position/status Chief Strategy Officer
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The exercise of nil-cost options over Ordinary
transaction Shares granted on 15 February 2017 under
the Company's 2009 Deferred Annual Bonus
Plan - Deferred Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 15,407 (Deferred)
=== ================================ ================ ==============================
GBP0.00 10,273 (Matching)
================ ==============================
d) Aggregated information
===
Aggregated volume 25,680
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===================================================================================
a) Name Mr D Redfern
=== ================================ =================================================
b) Position/status Chief Strategy Officer
=== ================================ =================================================
c) Initial notification/ Initial notification
amendment
=== ================================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== ================================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of nil-cost
options over Ordinary Shares under the
Company's Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
=== ================================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ===========================
GBP16.629 7,261 (Deferred)
=== ================================ ================ ===========================
GBP16.629 4,840 (Matching)
================ ===========================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 12,101
Price GBP16.629
=== ================================ =================================================
e) Date of the transaction 2020-02-17
=== ================================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ================================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =======================================================================================
a) Name Mr P Thomson
=== ================================= ====================================================
b) Position/status President, Global Affairs
=== ================================= ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================= ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================================
a) Name GlaxoSmithKline plc
=== ================================= ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================= ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================= ====================================================
b) Nature of the The exercise of nil-cost options over Ordinary
transaction Shares granted on 15 February 2017 under
the Company's 2009 Deferred Annual Bonus
Plan - Deferred Bonus and Matching Awards.
=== ================================= ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================= ================ ==============================
GBP0.00 7,302 (Deferred)
=== ================================= ================ ==============================
GBP0.00 4,869 (Matching)
================ ==============================
d) Aggregated information
===
Aggregated volume 12,171
Price GBP0.00
=== ================================= ====================================================
e) Date of the transaction 2020-02-17
=== ================================= ====================================================
f) Place of the N/A
transaction
=== ================================= ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===================================================================================
a) Name Mr P Thomson
=== ================================ =================================================
b) Position/status President, Global Affairs
=== ================================ =================================================
c) Initial notification/ Initial notification
amendment
=== ================================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== ================================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of nil-cost
options over Ordinary Shares under the
Company's Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
=== ================================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ===========================
GBP16.623 3,442 (Deferred)
=== ================================ ================ ===========================
GBP16.623 2,294 (Matching)
================ ===========================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 5,736
Price GBP16.623
=== ================================ =================================================
e) Date of the transaction 2020-02-17
=== ================================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ================================ =================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHXBLFLBLLEBBQ
(END) Dow Jones Newswires
February 20, 2020 09:00 ET (14:00 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
